InflaRx Revives Hope for Vilobelimab in Rare Skin Disorder Treatment with New Analyses

InflaRx is reviving hopes for vilobelimab after new analyses showed signs of efficacy in a Phase 3 trial for pyoderma gangrenosum, a rare skin disorder. The company anticipates meeting with the FDA to discuss a potential path forward, including alternative endpoints for future clinical studies. InflaRx will consider future vilobelimab development in collaboration with a partner, as it prioritizes izicopan development. The trial showed a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect.